+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemostasis and Tissue Sealing Agents Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • PDF Icon


  • 110 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 5764330
The hemostasis and tissue sealing agents market is expected to register a CAGR of 8.5% over the forecast period.

Key Highlights

  • The COVID-19 pandemic had a substantial effect on the hemostasis and tissue sealing agents market. The market expanded together with the rising significance of imbalanced hemostasis in COVID-19 patients in favor of a prothrombotic state, and their impact on prognosis also had a beneficial impact on market growth. Patients with COVID-19 were predicted to experience a critical illness, hemorrhage, mortality, and thrombosis by an elevated D-dimer level at the time of hospital admission. According to a research article published in PubMed in November 2021, hemostasis could be a risk factor for COVID-19 mortality and disease severity. As a result, the market expanded favorably both before and after COVID-19.
  • Factors such as the increasing number of surgical procedures as well as the rising number of road accidents are expected to significantly contribute to the growth of the hemostasis and tissue sealing agents market. For instance, according to a study published in the International Journal of Surgery in September 2020, 310 million major surgeries are carried out annually worldwide, with 40 to 50 million taking place in the United States and 20 million in Europe. Such factors are likely to boost the usage of hemostasis and tissue-sealing agents, thereby contributing to the studied market growth.
  • Moreover, the increasing prevalence of chronic blood disorders is also driving the market's growth. As per the 2022 update by the International Society on Thrombosis and Hemostasis, every year, there are approximately 10 million cases of venous thromboembolism worldwide. As per the same source, in Europe, there are 544,000 Deep Vein Thrombosis (DVT) related deaths every year. According to the Disorders of the Blood 2022 report by PhRMA published in May 2022, more than 3.2 million Americans are living with a bleeding disorder yearly. Therefore, an increase in the number of patients with blood disorders, along with the growing need to cater to various bleeding conditions, is likely to fuel the market for hemostasis and tissue-sealing agents.
  • The rise in the number of surgical procedures and the prevalence of chronic diseases (such as blood disorders) are significant factors driving the growth of the market studied. However, strict regulations on the approval of these agents coupled with the high costs of these agents are expected to hinder the growth of the market over the next five years.

Hemostasis & Tissue Sealing Agents Market Trends

General Surgery Segment is Expected to Hold a Significant Market Share

  • Hemostats consist of hemostatic agents, adhesives, and sealants that contain thrombin and play a prominent role in controlling blood loss during surgeries. The Journal of Medical Economics published a research study in April 2021, reporting that patients undergoing cardiac, vascular, noncardiac thoracic, and neuro surgeries immediately treated with active products as a first-line adjunctive hemostat may experience more effective or sustained hemostasis, resulting in a shorter hospital stay as well as lower risk of complications thereafter, thus lowering the total hospital costs.
  • As per the research study published in June 2021 by the German Heart Surgery Report, a total of 92,809 operations were classified as heart surgery procedures in a conventional manner, and the number of isolated heart transplantations increased by 2% to 340. According to the British Heart Foundation's February 2021 report, about 371,000 heart procedures and operations were performed in England in 2020. Hence, the high number of heart surgeries and operations being performed every year may boost the demand for hemostat agents that control bleeding.
  • In addition, increasing key strategic activities such as mergers and acquisitions and product launches by the key market players are anticipated to boost the segment's growth over the forecast period. For instance, in November 2022, Medtrade Products Ltd announced CE certification for its Uterine Hemostatic Tamponade, CELOX, which is a significant and state-of-the-art innovation that provides rapid and effective control of postpartum bleeding, a prevalent and severe complication of childbirth.
  • Thus, all aforementioned factors, such as the increasing number of surgical procedures and the product launches by key market players, are expected to boost the segment over the forecast period.

North America is Expected to Dominate the Market

  • North America is anticipated to dominate the hemostasis and tissue sealing agents market owing to the high clinical research and development budgets by both governments as well as public and private organizations, the presence of major manufacturers for the products, and a high number of surgical procedures.
  • The region's growing geriatric population has been fueling demand for less invasive surgical treatments, which in turn is promoting expansion in the market for hemostasis tissue sealing agents. According to the February 2022 update by the US Census Bureau, there were over 55 million senior citizens living in the United States in the year 2021, making up 17.1% of the total population. According to estimates, the total number of adults aged 65 and older is projected to rise to roughly 22% of the overall US population by 2050. This generation's population has a higher prevalence of obesity and chronic conditions than previous generations, which will likely change the amount and type of care they require.
  • Furthermore, a significant market exists for cutting-edge hemostasis products in North America due to the increased prevalence of cardiovascular diseases. The frequency of cardiac operations is likely to rise along with the prevalence of cardiovascular disorders in the area, which is predicted to enhance demand for hemostasis products and fuel market expansion. The growth can also be attributed to the presence of top pharmaceutical and biotechnology companies that are involved in technological developments and the presence of well-established healthcare infrastructure. For instance, in July 2021, Medcura Inc., a commercial-stage medical device company, in partnership with ASO LLC, a major United States manufacturer and supplier of first aid products, reported the launch of a high-performance, antibacterial hemostatic gel, Rapid-Seal, at a leading US drugstore chain. Thus, over the forecast period, technological advancements, a rising percentage of the geriatric population, and support from the government through reimbursement and innovation in products are expected to be the major drivers for the growth of the hemostasis and tissue sealing market.

Hemostasis & Tissue Sealing Agents Market Competitor Analysis

The hemostasis and tissue sealing agents market is moderately fragmented and consists of a number of major players, like Baxter International Inc., B Braun Holding GmbH & Co. KG, Becton, Dickinson & Company, Ethicon LLC, Integra Lifesciences Corporation, Johnson & Johnson, Medtronic PLC, Pfizer Inc., Smith & Nephew, Terumo Corporation, among others.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Blood Disorders
4.2.2 Increasing Number of Surgical Procedures and Road Accidents
4.2.3 Adoptability of Products across Multiple Conditions
4.3 Market Restraints
4.3.1 High Cost of the Products
4.3.2 Stringent Regulations and Approvals
4.4 Industry Attractiveness - Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.1 Topical Hemostats Mechanical Hemostats Active Hemostats Flowable Hemostats
5.1.2 Tissue Sealing Agents Fibrin Sealants Synthetic Sealants
5.1.3 Adhesives Cyanoacrylate Albumin and glutaraldehyde
5.2 By Material
5.2.1 Gelatin based Topical Hemostats
5.2.2 Collagen-based Topical Hemostats
5.2.3 ORC-based Topical Hemostats
5.2.4 Polysaccharide based Topical Hemostats
5.3 By Application
5.3.1 General Surgery
5.3.2 Minimally Invasive Surgery
5.3.3 Trauma
5.3.4 Hemophilia
5.3.5 Other Applications
5.4 By End-user
5.4.1 Hospitals
5.4.2 Ambulatory Surgical Centers
5.4.3 Other End Users
5.5 By Geography
5.5.1 North America United States Canada Mexico
5.5.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.5.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.5.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 B Braun Holding GmbH & Co. KG
6.1.3 Becton, Dickinson & Company
6.1.4 Ethicon LLC
6.1.5 Integra Lifesciences Corporation
6.1.6 Johnson & Johnson
6.1.7 Medtronic PLC
6.1.8 Pfizer Inc.
6.1.9 Smith & Nephew
6.1.10 Terumo Corporation

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Baxter International Inc.
  • B Braun Holding GmbH & Co. KG
  • Becton, Dickinson & Company
  • Ethicon LLC
  • Integra Lifesciences Corporation
  • Johnson & Johnson
  • Medtronic PLC
  • Pfizer Inc.
  • Smith & Nephew
  • Terumo Corporation